Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications inEurope (including theUnited Kingdom), Latin America and Other Key Countries - Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202...